Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11114272 | 0.98 | MAPK1 (0.31) | MAPK1KDM4EMAPTATM | |
| SCHEMBL9886141 | 0.81 | SLC6A3 (0.34) | MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL14141482 | 0.78 | ALDH1A1 (0.35) | MAPK1SLC6A3 | |
| SCHEMBL4023693 | 0.77 | TSHR (0.32) | MAPK1KDM4EMAPTSLC6A3 | |
| SCHEMBL10123519 | 0.77 | TSHR (0.32) | MAPK1KDM4EMAPTSLC6A3 | |
| Acetic Acid SCHEMBL7152399 | 0.76 | FFAR3 (0.41) | MAPK1KDM4EMAPTATM | |
| SCHEMBL28178052 | 0.75 | SLC6A3 (0.38) | MAPTNPC1RAB9ASLC6A3 | |
| SCHEMBL12200618 | 0.75 | — | — | |
| SCHEMBL14081363 | 0.75 | KDM4E (0.38) | MAPK1KDM4EMAPT | |
| SCHEMBL8197869 | 0.75 | KDM4E (0.38) | MAPK1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0281521-A2 | Herbicidal compositions | CIBA-GEIGY AG (CH) | 1988-09-07 | — | — | EP | claimed |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME CORP. (US) | 2012-07-12 | — | — | US | disclosed |
| US-8168649-B2 | Niacin receptor agonists, compositions containing such compounds and methods of treatment | Merk Sharp & Dohme Corp. (US) | 2012-05-01 | — | — | US | disclosed |
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2011-04-28 | — | — | US | disclosed |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | MERCK SHARP & DOHME LLC | 2010-06-10 | — | — | US | disclosed |
| WO-2009121033-A2 | SUBSTITUTED NITROGEN HETEROCYCLES AND SYNTHESIS AND USES THEREOF | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | WO | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | UNIVERSITY OF SOUTHERN CALIFORNIA (US) | 2009-10-01 | — | — | US | disclosed |
| EP-0281521-A2 | Herbicidal compositions | CIBA-GEIGY AG (CH) | 1988-09-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110098483-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | MAPK1 871/4885KDM4E 2916/4885MAPT 3189/4885 |
| US-20100144778-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, GPR119 | MAPK1 2198/4885KDM4E 4813/4885MAPT 2721/4885 |
| US-20090247766-A1 | Substituted Nitrogen Heterocycles and Synthesis and Uses Thereof | PAH, NAT1, NNT | MAPK1 871/4885KDM4E 2916/4885MAPT 3189/4885 |
| US-20120178750-A1 | Niacin Receptor Agonists, Compositions Containing Such Compounds and Methods of Treatment | HCAR1, HCAR2, FFAR1 | MAPK1 2049/4885KDM4E 4824/4885MAPT 2701/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.